Eli Lilly and Company $LLY Shares Newly Purchased by Vista Capital Partners Inc.
by Mitch Edgeman · The Markets DailyVista Capital Partners Inc. bought a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,103 shares of the company’s stock, valued at approximately $1,276,000.
A number of other hedge funds have also added to or reduced their stakes in the stock. Bank of America Corp DE bought a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. Jupiter Topco LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $4,667,180,000. Corient Private Wealth LP bought a new position in Eli Lilly and Company in the 2nd quarter valued at $764,116,000. BlackRock Inc. boosted its holdings in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. Finally, State Street Corp grew its position in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on LLY shares. Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective on the stock in a research report on Tuesday, September 15th. BMO Capital Markets restated an “outperform” rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. Scotiabank boosted their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 30th. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Friday. Finally, UBS Group raised their price target on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,416.64.
Read Our Latest Stock Analysis on LLY
Eli Lilly and Company Stock Performance
NYSE LLY opened at $1,444.05 on Monday. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,460.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a market capitalization of $1.36 trillion, a P/E ratio of 46.87, a P/E/G ratio of 1.73 and a beta of 0.40. The company has a fifty day moving average of $1,242.25 and a 200-day moving average of $1,110.30.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the prior year, the firm earned $7.02 earnings per share. The firm’s revenue was up 38.6% on a year-over-year basis. As a group, equities research analysts predict that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.
Insider Activity at Eli Lilly and Company
In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?